Bispecific antibodies (bsAbs), multispecific antibodies (msAbs), and fusion proteins offer several advantages over monoclonal antibodies (mAbs) in drug development, primarily through enhanced therapeutic efficacy, broader target engagement, and improved pharmacokinetics. However, the development of bsAbs, msAbs, and fusion proteins presents unique challenges in Chemistry, Manufacturing, and Controls (CMC) due to their structural complexity, heterogeneity, and functional diversity.

Altruist Biologics has a mature and comprehensive platform to address these challenges through advanced cell line development, process optimization, analytical characterization, and formulation strategies. Key challenges include mispaired impurities, aggregation, fragmentation, and complex potency assays, which are mitigated through optimized multi-gene vectors design, advanced purification techniques, and high-resolution analytical methods.